Trial Profile

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rosnilimab in Subjects With Moderate to Severe Ulcerative Colitis

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 31 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

31 Mar 2025 Last checked against ClinicalTrials.gov record.
12 Feb 2025 According to an AnaptysBio media release, top-line Week 12 Phase 2 data for rosnilimab in UC, now expected in Q4 2025.
14 Aug 2024 According to an AnaptysBio media release, company announced the pricing of an underwritten offering of 2,750,498 shares, the gross proceeds from this offering are expected to be approximately $100 million. The proceeds intended to be used primarily to accelerate and support the enablement of Phase 3 trials for ANB032in Phase 2b development in atopic dermatitis, rosnilimab in Phase 2b development in rheumatoid arthritis and Phase 2 development in ulcerative colitis.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com